We represent life sciences companies in high-stakes IP litigation and commercial disputes. Our clients range from start-ups developing cutting-edge technologies to producers of some of the world’s leading medicines. Regardless of the size of matter, we apply a lean, aggressive, trial-ready approach focused from the outset on achieving your business objectives.

We have the trial experience, technical ability and depth of talent to take on the largest, most complex global disputes. Our IP team has represented both plaintiffs and defendants in brand-versus-brand litigation where billions of dollars are at stake, and has advised biologic and biosimilar manufacturers on how to navigate the Biologics Price Competition and Innovation Act. Our trial lawyers also have extensive experience representing branded pharmaceutical companies in patent cases under the Hatch-Waxman Act, successfully defending numerous multi-million dollar a year medicines against generic challenges. Most of our matters have involved extensive coordination with parallel disputes abroad, including the EU and Asia, or post-grant proceedings and interferences at the U.S. Patent and Trademark Office.

In addition to our deep experience with small-molecule products, pharmaceutical formulations, biologics, medical devices, and diagnostics, we have extensive experience with emerging technologies such as CRISPR, CAR-T cells, and novel drug delivery vectors. We assist clients in transactions, due diligence, and patent strategy, and help smaller companies grow by counseling on how to protect, enforce and monetize their IP. 

We are nimble, creative, and highly-effective. Let us put our skills to work for you.

Gregory B. Sephton
Brian V. Slater

Craig Bolton
Thomas C. Frongillo
David L. Hecht
Amman Khan
Conor McDonough

Yi Wen Wu